ICD-10-CM Billable Code

E76.1

Mucopolysaccharidosis, type II

Clinical Classification Guidelines

Inclusion Terms

  • Hunter's syndrome

Medical Intelligence & Overview

Mucopolysaccharidosis type II, commonly known as Hunter's syndrome, is a rare genetic disorder that affects many parts of the body. It is classified under ICD-10 code E76.1. This condition is caused by a deficiency of the enzyme iduronate-2-sulfatase, leading to the accumulation of complex sugars called glycosaminoglycans (GAGs) in cells. The buildup results in progressive physical and developmental problems, varying in severity among individuals. Hunter's syndrome is inherited in an X-linked pattern, primarily affecting males.

Causes & Symptoms

Clinical Causes: Genetic mutation in the IDS gene on the X chromosome Inherited in an X-linked recessive manner, primarily affecting males Lack or deficiency of the enzyme iduronate-2-sulfatase Accumulation of glycosaminoglycans in various tissues and organs

Key Symptoms: Distinct facial features such as a prominent forehead and flat nasal bridge Joint stiffness and limited mobility Hearing loss and frequent respiratory infections Hepatosplenomegaly (enlarged liver and spleen) Short stature and skeletal abnormalities (dysostosis multiplex) Skin abnormalities like thickened skin Cardiac issues including valve problems Developmental delays and cognitive impairment in severe cases

Diagnostic & Treatment

Diagnosis Path: Diagnosis involves a combination of clinical evaluation and laboratory testing. Key steps include:

Treatment Protocols: While there is no cure for Hunter's syndrome, treatment aims to manage symptoms and improve quality of life. Options include:

Reimbursement claims with a date of service on or after October 1, 2015 require the use of ICD-10-CM codes.

Clinical Advice & FAQs

Billing Guidance

Is E76.1 a billable ICD-10 code?
Yes, E76.1 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.

Documentation

How do I report E76.1?
Clinical documentation must specify the nature of Mucopolysaccharidosis, type II and any associated comorbidities for accurate reporting.

Cite this Clinical Reference